rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Meta-analysis confirms semaglutide improves exercise capacity, blood pressure, and inflammation in HFpEF

RPEP-136352025Sobral, Milene Vitória Sampaio; Rodrigues, Livia Kneipp; Barbosa, Abner Mácola Pacheco; da Rocha, Naila Camila; Moulaz, Isac Ribeiro; Dos Santos, João Pedro Pereira; Oliveira, Bruno Henrique Couto; Moreira, João Lucas de Magalhães Leal; Pacagnelli, Francis Lopes; Guida, Camila Mota
evidence
The takeaway

Meta-analysis of 1,463 HFpEF patients shows semaglutide significantly increases 6-minute walk distance (+16.2m), lowers systolic BP (-2.2 mmHg), and reduces CRP and NT-proBNP versus placebo.

+16.2m walk distance

Semaglutide improved exercise capacity in HFpEF patients with zero heterogeneity across studies, alongside blood pressure, CRP, and NT-proBNP reductions

What the researchers found

6MWD: +16.2m (p<0.001, I²=0%); SBP: -2.22 mmHg (p<0.01, I²=0%); CRP: ratio 0.59 (p<0.001, I²=51%); NT-proBNP: ratio 0.81 (p<0.001, I²=0%). 3 studies, 1,463 patients, 52 weeks.

Why it matters

HFpEF is the most common form of heart failure with limited treatment options. Quantifying semaglutide's benefits across multiple outcomes strengthens the case for its use in this condition.

How the study worked

Systematic review and meta-analysis of 2 RCTs + 1 non-randomized cohort from EMBASE, PubMed, Cochrane. Random-effects models. 52-week follow-up.

What this study cannot tell us

Only 3 studies available. Mix of RCTs and observational. CRP showed moderate heterogeneity (I²=51%). No mortality or hospitalization endpoint.

How to read the evidence

Meta-analysis of 3 studies including 2 RCTs. Zero heterogeneity for most outcomes. Moderate evidence base.

When this study was published

Published in 2025.

The bigger picture

Semaglutide is emerging as one of the first truly effective medical therapies for HFpEF, improving exercise capacity, reducing cardiac stress biomarkers, and lowering inflammation and blood pressure simultaneously.

Questions still open

  • Will semaglutide reduce HFpEF hospitalization and mortality in dedicated outcome trials?
  • Is the +16.2m walk distance improvement clinically meaningful for patients?
  • Does NT-proBNP reduction predict improved long-term outcomes?

Common questions

Does semaglutide help heart failure patients exercise more?
Yes. This meta-analysis found semaglutide helped HFpEF patients walk 16 meters farther in 6 minutes—a meaningful improvement in daily functional capacity. It also lowered blood pressure, inflammation, and cardiac stress markers.
How does semaglutide help heart failure?
Semaglutide addresses HFpEF through multiple mechanisms: reducing weight (which decreases the workload on the heart), lowering blood pressure, reducing inflammation (CRP), and decreasing cardiac stress (NT-proBNP). These combined effects improve how well patients can exercise and function daily.

Read the original research

Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 25(4), 461-467

View on PubMed ↗Publisher’s paper ↗

Citation

Sobral, Milene Vitória Sampaio; Rodrigues, Livia Kneipp; Barbosa, Abner Mácola Pacheco; da Rocha, Naila Camila; Moulaz, Isac Ribeiro; Dos Santos, João Pedro Pereira; Oliveira, Bruno Henrique Couto; Moreira, João Lucas de Magalhães Leal; Pacagnelli, Francis Lopes; Guida, Camila Mota. (2025). Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.. American journal of cardiovascular drugs : drugs, devices, and other interventions, 25(4), 461-467. https://doi.org/10.1007/s40256-025-00721-4